reVision Therapeutics
Founder
Aleksey Krylov
Founder @BIOBOHEMIA, @Ftera Advisors • Worked at @SG Cowen, @CiG Private Equity and Venture Partners • Investor @Altilium Power Development,
Founder @BIOBOHEMIA, @Ftera Advisors • Worked at @SG Cowen, @CiG Private Equity and Venture Partners • Investor @Altilium Power Development,
There was a problem loading your content.
Experience
BIOBOHEMIA
Founder
PILLAR ROCK USA
Advisor
Ftera Advisors
Founder, Managing Partner
We are a financial consulting firm. We work with early-stage and mature small- and medium-size enterprises. We prefer working within health care but have delivered positive... more outcomes for businesses in consumer/e-commerce, software/IT/digital media, cleantech, energy/mining and agriculture sectors. We aid clients with fundraising, M&A, turnaround and strategic business development. We also step-in to fill interim CEO, CFO or COO roles. Selectively, we invest principal capital in businesses.
Sellas Life Sciences (NASDAQ:SLS)
Chief Financial Officer (Interim)
Achieved multiple milestones for SELLAS, including the completion of the company's reverse merger and the closing of a financing. Managed financial operations of this Nasdaq-listed... more biotech company.
CHR
Business Development
Sourcing and structuring VC and PE investments in various growth stage companies.
CiG Private Equity and Venture Partners
Vice President, Private Equity and Merchant Banking
Ener1 Group
Private Equity Associate and Special Assistant to the CEO
SG Cowen
Investment Banking Analyst
Equity Private Placements Group
Employee
Founder
Employee
Advisor
Education
About
Achievements
Aleksey Krylov is a seasoned biotech and medtech Chief Financial Officer (CFO). With a venture investing and investment banking background, his track record includes over 70 fundraising, going-public, and M&A transactions. Aleksey is a natural leader with experience managing daily operations for high-growth organizations. He consults at https://www.tialma.com and advises startups often pro bono at https://www.alekseykrylov.com.
CFO of CytoImmune Therapeutics, ~$110 million in funding, workforce expansion from five to over 60 employees
CFO of DIH International, first audit with Big 4, readiness to file F-1.
CFO of SELLAS Life Sciences, exit, Nasdaq listing.
Skills
Locations